Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 21;26(2):213–228. doi: 10.1038/s41418-018-0124-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Authors 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 8 — Conditional expression of NLRP3 active mutant in microglia exacerbates motor dysfunctions and dopaminergic neuronal loss in MPTP-treated mice. a Immunoblots from Cx3Cr1^Cre-ER/+Nlrp3^D301NneoR/+ mouse mixed glial cells treated with tamoxifen (1 μM, 24 h), replenished with the medium containing LPS (0.25 μg ml⁻¹, 3 h), followed by ATP (2 mM, 40 min). b–g Control (Cx3Cr1^{Cre-ER/Cre-ER}Nlrp3^+/+) or NLRP3 mutant mice (Cx3Cr1^Cre-ER/+Nlrp3^D301NneoR/+) were treated with tamoxifen for 5 days, followed by the administration of MPTP for additional 3 days. b The severity of hindlimb clasping in MPTP-treated control or Nlrp3 (D301N)-expressing mice. (control, n = 8; Nlrp3 (D301N), n = 7). c The latent time to hold the bar in the catalepsy test in MPTP-treated control or Nlrp3 (D301N)-expressing mice (control, n = 8; Nlrp3 (D301N), n = 7). d Quantification of relative TH-positive cells per DAPI in the confocal images as shown in (e) (control, n = 5; Nlrp3 (D301N), n = 3). f Quantification of relative Iba1-positive cells per DAPI in the confocal images as shown in (g) (control, n = 5; Nlrp3 (D301N), n = 3). e, g Representative immunofluorescence image of the fixed brain sections containing the SN of MPTP-treated control or Nlrp3 (D301N)-expressing mice following tamoxifen treatment after staining with anti-TH antibody (green, e) or anti-Iba1 antibody (red, g). DAPI represents the nuclear signal (blue). Scale bars, 200 μm. h Cx3Cr1^{Cre-ER/Cre-ER}Nlrp3^+/+ or Cx3Cr1^Cre-ER/+Nlrp3^D301NneoR/+ mice microglia was treated with tamoxifen (1 μM, 24 h), and co-cultured with SH-SY5Y cells. Flow cytometric analysis of co-cultured Nlrp3^+/+ or Nlrp3^D301N/+ microglia and SH-SY5Y cells treated with MPTP (40 μM, 16 h), followed by the treatment with ATP (2.5 mM, 15 min), replenished with fresh medium and incubated for additional 24 h, after staining with anti-CD45 antibody and PI. The PI histograms of CD45-negative SH-SY5Y cells were displayed. Data were expressed as the mean ± SEM. Asterisks indicate significant differences (*P < 0.05, **P < 0.01)